Is Guardant Health Inc (GH) a risky stock?
As of July 21, 2026, Clavix grades Guardant Health Inc (GH) C- for risk, a composite score of 54 out of 100 on an A+ to F scale, which puts GH in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind GH's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how GH scores on each, as of July 21, 2026.
What's moving GH's risk right now
Company-specific signals Clavix flags behind GH's current grade, drawn from recent news and filings as of July 21, 2026.
Guardant posted 48% revenue growth but keeps losing money and burning cash. Q2 2026 results are due after the close on July 30, which will show whether the strong top-line is starting to close the profitability gap.
Positive results from rival Freenome's blood-based cancer screening study eased worries it could displace Guardant's similar test. Separately, Guggenheim forecasts strong price appreciation for the stock.
Canaccord Genuity raised its Guardant Health price target by roughly 52% to $205, citing confidence in the company's near-term growth trajectory and potentially drawing more institutional buyers.
What a C- grade means
On the Clavix A+ to F scale, GH's composite of 54 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell GH or any security. Grades are risk indicators, not predictions of return. Data may be delayed.